A Study of LY2157299 in Participants With Hepatocellular Carcinoma
H9H-MC-JBAK - ClinicalTrials.gov - NCT01246986
The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Liver CancerWhat the trial is testing?
Galunisertib, Sorafenib, RamucirumabCould I receive a Placebo?
NoEnrollment Goal
204Trial Dates
Mar 30, 2011 - Dec 24, 2019How long will I be in the trial?
Trial Phase
IILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo